Acute Optic Neuritis Market Outlook 2026-2036: Neuroprotection Moves Into Phase 3 | Thelansis

Acute Optic Neuritis is shifting from a steroid-only market toward its first potential neuroprotective therapy, with the first Phase 3 trial now underway. Thelansis has published two new reports covering the market, pipeline and unmet needs across the 8MM (US, EU4, UK, Japan and China).

Executive Summary
Acute Optic Neuritis (AON) is a sudden inflammation of the optic nerve. It can cause eye pain and vision loss, and in some patients the damage is permanent. For decades, care has centered on high-dose steroids to speed recovery, with no approved therapy that protects the nerve itself.

That may be about to change. Thelansis has released two new reports: Acute Optic Neuritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036) and Acute Optic Neuritis Emerging Therapy, Unmet Needs & TPP Insights Report (2026). Together they show how a small, steroid-dominated market is positioned for its first real shift in years.

Looking for patient-based forecasts, pipeline benchmarking, and launch scenarios? Explore the full Optic Neuritis Market Outlook and Forecast Report here: https://thelansis.com/reports/optic-neuritis-market-outlook-forecast/

Key Emerging Players or Therapies
The late-stage story is led by neuroprotection:
• Oculis' Privosegtor is a peptoid small molecule seen as a potential first neuroprotective therapy for AON, with Orphan Drug designation from both the FDA and the EMA.
• The FDA granted Breakthrough Therapy designation based on the Phase 2 ACUITY trial, and the EMA has granted PRIME designation.
• The first patient has been treated in the Phase 3 PIONEER-1 trial, and the FDA agreed under a Special Protocol Assessment that its design could support a new drug application.
• In Phase 2, Privosegtor combined with steroids improved low-contrast visual acuity through month 6, with anatomical signs consistent with neuroprotection. Oculis reported an average 18-letter gain on the low-contrast chart at month 3.
• Oculis is acquiring all worldwide development and commercial rights to Privosegtor from Accure, and plans an IND submission for acute MS relapses in Q4 2026.

Want to see how emerging candidates compare against these expectations? Access the Optic Neuritis Emerging Therapy, Unmet Needs & TPP Insights Report: https://thelansis.com/reports/optic-neuritis-emerging-therapy-with-unmet-needs-and-tpp-insights/

Key Current Therapies or Standard of Care
• High-dose intravenous methylprednisolone remains the standard approach across the 8MM. It speeds visual recovery but is not shown to change the final visual outcome.
• Plasma exchange is sometimes used in severe or steroid-unresponsive cases.
• Diagnosis increasingly includes MRI and antibody testing (AQP4 and MOG) to separate MS-related cases from NMOSD and MOGAD, which have very different long-term treatment paths.
• Practice varies across the US, Europe, Japan and China, which shapes how quickly new options could be adopted.

Key Market Drivers/Trends
• First-in-class potential: there is currently no specific therapy approved for acute optic neuritis, so an approval could reset the market.
• Regulatory tailwinds: Breakthrough, PRIME and Orphan status can shorten timelines and support strong pricing and access positioning.
• Better diagnosis: wider antibody testing and imaging mean patients reach the right care pathway earlier.
• Adjacent opportunity: Oculis is also running a registrational trial in NAION and plans to study acute MS relapses, widening the commercial story for neuro-ophthalmology.

Key Unmet Need & KOL Expectations
• The central gap is protecting the optic nerve during the acute attack, so patients keep more vision long term.
• Experts want therapies that work alongside steroids and are easy to deliver in routine neurology and ophthalmology settings.
• Clinicians look for measurable, meaningful outcomes, such as retinal nerve fiber layer preservation and improved low-contrast vision, rather than recovery speed alone.
• The leading Phase 3 design tests the drug on top of standard methylprednisolone, which points to add-on use as the most realistic first step.

TPP Insights
The Thelansis TPP report tests what an ideal AON therapy would need to look like to win with physicians and payers:
• Clear visual acuity benefit on top of standard steroids
• Evidence of structural nerve protection
• A clean safety profile and simple dosing
• Fit across patient groups, with and without MS

Commercial Opportunity
Acute optic neuritis is a rare, acute condition, but it offers a clear path for a first-to-market product: a well-defined treatment window, a specialist prescriber base, and no approved neuroprotective therapy today. For companies, the 2026-2036 outlook helps with: sizing patient pools across the 8MM, including China, timing launches and planning market access and spotting partnership and licensing opportunities in neuro-ophthalmology

Get Thelansis complete market forecast, competitive landscape and TPP insights report here:
• Optic Neuritis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036): https://thelansis.com/reports/optic-neuritis-market-outlook-forecast/?utm_source=openpr&utm_medium=pr&utm_campaign=on_mo

• Optic Neuritis Emerging Therapy, Unmet Needs & TPP Insights Report (2026):https://thelansis.com/reports/optic-neuritis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=on_tpp

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

This release was published on openPR.